Continuous Glucose Monitoring Market Size, Share & Industry Analysis, By Product Type (Sensors and Sensor Assemblies, Transmitters, Receivers and Readers, and Applicators and Accessories), By Technology (Enzymatic Electrochemical Sensing, Fluorescence-based Optical Sensing, and Others), By Clinical Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, and Others), By Distribution Channel (Retail and Specialty Pharmacies, DME and Medical Supply Distributors, Manufacturer-direct Channels, and Others), and Regional Forecast, 2026-2034

The global continuous glucose monitoring market size was valued at USD 13.86 billion in 2025. The market is projected to grow from USD 15.52 billion in 2026 to USD 33.61 billion by 2034, exhibiting a CAGR of 10.1% during the forecast period.

Continuous Glucose Monitoring (CGM) systems are wearable or implantable medical devices that track glucose levels continuously or at frequent intervals, mainly through interstitial-fluid sensing, and relay readings to a receiver, smartphone, smartwatch, or connected insulin-delivery platform. CGM provides trend information, alerts, and a more complete view of glycemic patterns throughout the day and night. The market includes sensors and sensor assemblies, transmitters, receivers and readers, and applicators and accessories sold through prescription, over-the-counter, pharmacy, DME, and manufacturer-direct channels.

Market growth is being supported by the expanding diabetes population, wider reimbursement, rising use among people with type 2 diabetes, and the shift toward connected and automated diabetes management. The International Diabetes Federation estimated that 589 million adults aged 20-79 were living with diabetes in 2024, creating a large and expanding pool of potential users. Product miniaturization, longer sensor wear, simpler insertion, and smartphone connectivity are further improving acceptance.

Abbott Laboratories, DexCom, Inc., and Medtronic held the largest market share, driven by increased investments and strategic initiatives, including new launches, collaborations, and partnerships.

CONTINUOUS GLUCOSE MONITORING MARKET TRENDS

Longer-Wear Sensors, AI-Enabled Insights, and Connected Ecosystems to Transform CGM Use

The market is moving toward longer-wear, smaller, smarter, and more connected glucose-sensing platforms. Manufacturers are extending sensor life to reduce replacement burden while embedding greater intelligence into companion applications and connected care ecosystems. Senseonics’ Eversense 365, approved in the U.S. in 2024 and commercially launched in Europe in 2026, demonstrates the shift toward year-long implantable monitoring, while newer transcutaneous systems are also extending wear duration.

At the same time, software is becoming a more important part of the user experience. Dexcom introduced a generative-AI platform for Stelo in 2024 to provide more personalized glucose-related insights, reflecting the broader movement toward predictive analytics and individualized guidance. Integration with smartphones, smartwatches, insulin pumps, automated insulin-delivery systems, and cloud-based clinician platforms is also increasing. Consequently, competition is increasingly being shaped by sensor accuracy, wear convenience, interoperability, personalized interpretation, connectivity, and the ability to integrate continuous monitoring naturally into daily diabetes management.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Diabetes Burden and Broader CGM Adoption to Propel Market Growth

The growing burden of diabetes, together with broader clinical use of CGM, is a central factor driving continuous glucose monitoring market growth. CGM adoption was initially concentrated among people with type 1 diabetes and those using intensive insulin therapy. Still, its role is widening across type 2 diabetes, basal-insulin users, and selected non-insulin populations. This expansion is being reinforced by easier product access, improving reimbursement, and a stronger focus on time-in-range and day-to-day glucose variability rather than isolated glucose measurements.

The commercial momentum of major manufacturers also reflects this wider adoption. Dexcom reported serving approximately 3.5 million customers globally at the end of 2025, while Abbott reported USD 6.8 billion in Diabetes Care revenue for 2024, with FreeStyle Libre serving as a major growth platform. As physicians increasingly use CGM data to personalize treatment and patients become more comfortable with wearable monitoring, the technology is moving from a specialized diabetes-management tool toward a broader standard of care, supporting sustained demand for sensors and related components.

MARKET RESTRAINTS

High Recurring Costs and Uneven Reimbursement to Limit Wider Adoption

Despite strong clinical acceptance, the recurring cost of CGM remains a meaningful restraint, particularly in markets where reimbursement is limited, fragmented, or tied to narrow eligibility criteria. Continuous use requires repeated sensor purchases, while some systems also involve transmitters, receivers, insertion procedures, or subscription-related costs. For patients without adequate insurance coverage, these recurring expenses can make long-term adherence difficult, especially when lower-cost blood glucose meters remain available.

Reimbursement rules also vary considerably between countries and even across payers within the same country, creating uneven access. In the U.S., Medicare coverage of CGM supplies is linked to specific eligibility and durable medical equipment requirements. CMS states that the supply allowance is not covered when a beneficiary never uses a qualifying DME receiver or insulin infusion pump to display CGM data. These conditions can slow penetration among lower-income groups and users in less-developed reimbursement environments. Longer-wear sensors, pharmacy access, and direct-to-consumer models are helping, but affordability remains a barrier to population-level adoption.

MARKET OPPORTUNITIES

Expansion into Non-Insulin Type 2 Diabetes and OTC Use to Create New Revenue Opportunities

A major growth opportunity lies in extending CGM beyond the traditional insulin-treated diabetes population. Large numbers of people with type 2 diabetes who do not use insulin, along with individuals with prediabetes or other forms of dysglycemia, remain underpenetrated by continuous monitoring. Regulatory changes are beginning to open this population to new products and commercial models. In August 2024, Dexcom launched Stelo in the U.S. as an over-the-counter glucose biosensor for adults not using insulin, removing the prescription requirement for its intended population. Abbott has similarly expanded into over-the-counter monitoring with Lingo and Libre Rio, broadening glucose sensing toward diabetes management and metabolic-health applications. This creates room for manufacturers to develop consumer-facing channels, subscription programs, digital coaching tools, and pharmacy-led access models. Over time, stronger evidence around behavioral modification, treatment optimization, and earlier glycemic intervention could support wider adoption in primary care and preventive health, substantially increasing the addressable population beyond intensive insulin management.

MARKET CHALLENGES

Maintaining Accuracy, Reliability, and Digital Safety at Scale to Remain a Key Challenge for Manufacturers

As CGM becomes more deeply integrated into treatment decisions and automated insulin delivery, manufacturers face a growing challenge in maintaining sensor accuracy, software reliability, cybersecurity, and uninterrupted data delivery at scale. Small errors can carry greater clinical consequences when glucose readings are used to guide insulin dosing or trigger automated responses. The FDA’s 2025 correction involving certain Dexcom G7 and ONE+ applications highlighted how a software-design issue could result in missed sensor-failure alerts. Abbott also initiated a 2025 correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors after identifying the potential for incorrect low glucose readings related to a manufacturing issue. These developments underline the need for robust quality systems spanning sensor chemistry, manufacturing, firmware, mobile applications, and wireless connectivity. As portfolios expand across more countries and clinical populations, companies must also manage differing regulatory and post-market surveillance requirements. Sustaining user confidence will therefore depend on consistent real-world performance, rapid corrective action, secure connectivity, manufacturing control, and transparent communication with patients and healthcare professionals.

Segmentation Analysis

By Product Type

Recurring Sensor Replacement and Expanding User Base to Keep Sensors and Sensor Assemblies Dominant

Based on product type, the market is segmented into sensors and sensor assemblies, transmitters, receivers and readers, and applicators and accessories.

The sensors and sensor assemblies segment is expected to account for the largest continuous glucose monitoring market share in the coming years, as sensors are the recurring-use component of most CGM systems. Transcutaneous sensors generally require regular replacement, creating a steady replenishment cycle and high annual revenue per active user. The expanding installed CGM user base further magnifies sensor demand.

The applicators and accessories segment is projected to grow at a CAGR of 11.3% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Technology

Proven Performance and Manufacturing Scale to Sustain Enzymatic Electrochemical Sensing Leadership

By technology, the market is classified into enzymatic electrochemical sensing, fluorescence-based optical sensing, and others.

Enzymatic electrochemical sensing is expected to hold the largest market share over the forecast period, as it underpins the dominant transcutaneous CGM platforms and combines established sensor chemistry with scalable, miniaturized electronics. The technology supports frequent glucose measurements, factory calibration, wireless transmission, and compact disposable form factors. Moreover, the segment is projected to hold a 99.6% share in 2026.

The fluorescence-based optical sensing segment is estimated to grow at a CAGR of 21.6% during the forecast period.

By Clinical Indication

Large Patient Pool to Drive Type 2 Diabetes Dominance

By clinical indication, the market is classified into type 1 diabetes, type 2 diabetes, gestational diabetes, and others.

Type 2 diabetes is expected to hold the largest share over the forecast period, as it represents the largest diabetes population and CGM use is extending well beyond intensive insulin therapy. Moreover, the segment is projected to hold a 54.3% share in 2026.

The gestational diabetes segment is estimated to grow at a CAGR of 12.2% during the forecast period.

By Distribution Channel

Convenient Access and Expanding Consumer Availability to Boost Retail and Specialty Pharmacies Segment Growth

On the distribution channel, the market is classified into retail and specialty pharmacies, DME and medical supply distributors, manufacturer-direct channels, and others.

Retail and specialty pharmacies are expected to account for the largest share over the forecast period, as CGM shifts from a specialist-device model toward routine outpatient diabetes management. Pharmacy access reduces procurement friction, allows patients to obtain sensors alongside other diabetes therapies, and can simplify access compared with traditional equipment channels. Furthermore, the segment is set to hold a 48.9% share in 2026.

The manufacturer-direct channels segment is projected to grow at a CAGR of 13.8% during the forecast period.

Continuous Glucose Monitoring Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the largest revenue share in 2024, at USD 5.45 billion, and was valued at USD 6.18 billion in 2025. Market growth is supported by high diabetes prevalence, established reimbursement pathways, strong physician acceptance, and rapid adoption of newer CGM technologies in the U.S. and Canada. The International Diabetes Federation projects the number of people with diabetes in the North America & Caribbean region to increase by approximately 22% by 2050, sustaining the long-term addressable patient base.

U.S. Continuous Glucose Monitoring Market

In 2026, the U.S. market is projected to represent USD 6.29 billion, capturing 40.5% of total global revenues.

Europe

Europe is expected to achieve a CAGR of 8.4% in the coming years, the second-highest globally, reaching USD 3.69 billion in 2026. The IDF estimates that around 66 million adults in Europe are living with diabetes, with the number expected to increase by about 10% by 2050, providing a sustained clinical demand base.

U.K. Continuous Glucose Monitoring Market

The U.K. market is projected to reach USD 0.55 billion in 2026, accounting for 3.5% of global revenues.

Germany Continuous Glucose Monitoring Market

The market in Germany is projected to reach about USD 0.70 billion in 2026, representing roughly 4.5% of global revenues.

Asia Pacific

In 2026, the Asia Pacific market is predicted to be valued at USD 3.79 billion, ranking as the third-largest globally. The market offers substantial growth potential, as it combines an exceptionally large diabetes population with comparatively lower CGM penetration in several major countries.

Japan Continuous Glucose Monitoring Market

The market in Japan is projected to generate approximately USD 0.72 billion in 2026, contributing nearly 4.6% of global revenues.

China Continuous Glucose Monitoring Market

The market in China is set to reach approximately USD 1.39 billion in 2026, contributing about 9.0% of global revenues.

India Continuous Glucose Monitoring Market

The market in India is set to reach approximately USD 0.43 billion in 2026, corresponding to about 2.8% of global revenues.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are anticipated to witness moderate market growth, with Latin America expected to reach around USD 0.70 billion in 2026. The Latin America market is expected to grow from a comparatively smaller base as the diabetes burden rises and advanced glucose-monitoring technologies become more accessible in major markets such as Brazil and Mexico. The Middle East & Africa market is expected to expand as a high and rapidly increasing diabetes burden combines with relatively low current penetration of advanced glucose-monitoring technologies.

GCC Continuous Glucose Monitoring Market

In 2026, the GCC market is expected to generate approximately USD 0.20 billion, accounting for nearly 1.3% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Strong Market Concentration and Continuous Product Innovation to Intensify Competition

The global continuous glucose monitoring market has a relatively concentrated competitive structure, led primarily by Abbott Laboratories, DexCom, Inc., and Medtronic, which benefit from large installed user bases, established reimbursement access, extensive distribution networks, and strong integration with digital diabetes-management ecosystems.

• For instance, Abbott’s FreeStyle Libre platform has more than 7 million users globally, while Dexcom generated USD 4.66 billion in revenue in 2025, highlighting the commercial scale of the leading participants.

Competition is increasingly shifting beyond basic glucose-monitoring accuracy toward longer sensor wear, smaller form factors, lower cost, factory calibration, smartphone connectivity, OTC availability, predictive analytics, and interoperability with automated insulin-delivery systems. Roche is strengthening competition through its AI-enabled Accu-Chek SmartGuide, while Senseonics differentiates itself through the 365-day implantable Eversense system. Regional manufacturers, particularly from Asia, are also increasing pricing pressure and expanding CGM availability, making technological differentiation, reimbursement access, manufacturing scale, and geographic expansion increasingly important competitive factors.

LIST OF KEY CONTINUOUS GLUCOSE MONITORING COMPANIES PROFILED

• Abbott Laboratories (U.S.)
• DexCom, Inc. (U.S.)
• Medtronic plc (Ireland)
• Senseonics Holdings, Inc. (U.S.)
• Sinocare Inc. (China)
• Shenzhen SiBionics Technology Co., Ltd. (China)
• MicroTech Medical (Hangzhou) Co., Ltd. (China)
• Medtrum Technologies Inc. (China)
• i-SENS, Inc. (South Korea)
• Infinovo Medical Co., Ltd. (China)

KEY INDUSTRY DEVELOPMENTS

• June 2026: Senseonics and Welldoc announced a strategic partnership to develop a next-generation mobile application for Eversense 365, incorporating improved digital-health integration and leveraging Welldoc's AI-powered platform for potential future functionality.
• February 2026: LifeScan entered into a strategic partnership with i-SENS to introduce a CGM under the OneTouch Vita brand. Initial launches are planned in Germany, Ireland, Portugal, and Belgium, followed by broader geographic expansion.
• January 2026: Senseonics received CE Mark approval for Eversense 365 under the EU Medical Device Regulation, allowing commercialization of its one-year implantable CGM system in the European Union.
• September 2025: The FDA cleared Medtronic's SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration of the Abbott-made Instinct sensor with MiniMed 780G. The FDA also approved MiniMed 780G for adults with insulin-requiring type 2 diabetes.
• August 2025: Abbott launched FreeStyle Libre 2 Plus in India, introducing automatic glucose readings every minute and optional high- and low-glucose alarms through compatible smartphones.
• April 2025: The FDA approved Simplera Sync for use with the MiniMed 780G system. The disposable, all-in-one sensor expanded Medtronic's CGM options alongside Guardian 4.
• April 2025: The FDA cleared Dexcom G7 15 Day for adults aged 18 years and above with diabetes. The new version extended sensor wear to 15.5 days, reducing the number of sensors required for continuous use.

REPORT COVERAGE

The report provides an in-depth analysis of all continuous glucose monitoring market segments, highlighting key drivers, trends, opportunities, restraints, and challenges. It also provides insights into technological advancements, key industry developments, company market share analysis, and profiles of leading companies. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope and Segmentation

Bottom-Up Approaches

Approach 1: Revenues and Market Share of Major CGM Players

• Collection of CGM-specific revenues from annual reports, SEC filings, investor presentations, earnings releases, and official company disclosures of Abbott, Dexcom, Medtronic, Senseonics, Sinocare, and other manufacturers.
• Estimation of company market shares based on CGM revenues, geographic presence, product portfolio, installed user base, and commercial availability.
• Triangulation of company-level revenues with regional and country-level CGM adoption to derive the global market estimate.

Approach 2: Product Volume, Replacement Cycle, and Pricing Analysis

• Identification of major CGM products and estimation of sensor, transmitter, receiver, and accessory volumes across key countries.
• Assessment of sensor wear duration, annual replacement frequency, active user base, and manufacturer-level average selling prices.
• Multiplication of estimated product volumes by manufacturer selling prices, followed by aggregation across countries and regions to derive market value.

Approach 3: Patient Eligibility and CGM Adoption Model

• Assessment of diagnosed and CGM-eligible populations across Type 1 diabetes, Type 2 diabetes, gestational diabetes, and other clinical indications.
• Mapping of CGM penetration based on insulin use, treatment intensity, reimbursement coverage, affordability, and product availability.
• Multiplication of active CGM users by annual device consumption and average manufacturer-level expenditure to estimate country and regional markets.

Top-Down Approach

Approach 1: Country-Level Diabetes Burden and CGM Penetration Analysis

• Analysis of diabetes prevalence, diagnosed patient population, insulin-treated population, healthcare expenditure, reimbursement, and technology adoption across key countries.
• Estimation of the proportion of eligible patients using CGM based on clinical guidelines, reimbursement policies, product availability, and market maturity.
• Aggregation of country-level CGM demand estimates and validation against company revenues and product-volume calculations to derive regional and global market size.

List of Key Sources

• International Diabetes Federation, WHO, CDC, ADA, EASD, national diabetes registries, and national health ministries.
• FDA, European Commission, PMDA/MHLW, NMPA, CDSCO, TGA, CMS, NICE/NHS, NDSS, and other regulatory and reimbursement authorities.
• Annual reports, SEC/stock-exchange filings, investor presentations, earnings releases, company press releases, product labels, regulatory approvals, and product catalogs.
• CGM user-base disclosures, sensor wear duration, product launches, reimbursement changes, geographic expansions, partnerships, and manufacturing-capacity announcements.

Primary Interviews

Supply-Side Interviews: 60%

• Key Respondents: CGM manufacturers, sensor/component suppliers, distributors, DME suppliers, pharmacy-channel participants, sales executives, marketing managers, and market-access professionals.
• Interviews will validate market size, pricing, product volumes, replacement frequency, distribution mix, competitive positioning, and regional growth trends.

Demand-Side Interviews: 40%

• Key Respondents: Endocrinologists, diabetologists, diabetes educators, healthcare providers, procurement professionals, payers, and reimbursement experts.
• Interviews will assess CGM penetration, patient eligibility, prescribing patterns, reimbursement access, treatment preferences, affordability, and adoption across countries and clinical indications.

Final Market Triangulation

• Results from company-revenue analysis, product-volume analysis, patient-adoption modeling, country-level analysis, secondary research, and primary interviews will be compared and reconciled.
• Manufacturer-level revenues will be used as the final valuation basis. In contrast, distributor margins, pharmacy markups, healthcare-service revenues, and insulin-pump revenues outside the identifiable CGM component will be excluded to prevent double counting.